BioPorto Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

BioPortoDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -0.03% zurückgegangen, während in der Branche Biotechs die Gewinne wachsen. Die Umsätze sind gewachsen mit einer durchschnittlichen Rate von 6.7% pro Jahr.

Wichtige Informationen

-0.03%

Wachstumsrate der Gewinne

18.8%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie	18.7%
Wachstumsrate der Einnahmen	6.7%
Eigenkapitalrendite	-70.8%
Netto-Marge	-175.6%
Letzte Ertragsaktualisierung	30 Sep 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Here's Why We're Not Too Worried About BioPorto's (CPH:BIOPOR) Cash Burn Situation

Oct 16

Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth

May 28

BioPorto A/S' (CPH:BIOPOR) Path To Profitability

Mar 01

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

Jan 24

A Look At BioPorto's (CPH:BIOPOR) CEO Remuneration

Dec 20

The BioPorto A/S (CPH:BIOPOR) Analysts Have Been Trimming Their Sales Forecasts

Nov 23

BioPorto A/S (CPH:BIOPOR) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Nov 21

Aufschlüsselung der Einnahmen und Ausgaben

Wie BioPorto Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

CPSE:BIOPOR Einnahmen, Ausgaben und Erträge (DKK Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
30 Sep 24	35	-61	61	27
31 Mar 24	32	-54	51	26
31 Dec 23	31	-56	55	25
30 Sep 23	33	-70	62	28
30 Jun 23	30	-78	63	32
31 Mar 23	31	-75	65	33
31 Dec 22	29	-76	63	35
30 Sep 22	27	-68	58	36
30 Jun 22	27	-62	56	33
31 Mar 22	25	-59	51	30
31 Dec 21	24	-57	50	30
30 Sep 21	25	-54	48	27
30 Jun 21	24	-60	48	29
31 Mar 21	25	-62	48	31
31 Dec 20	23	-62	49	28
30 Sep 20	22	-64	45	30
30 Jun 20	24	-68	54	29
31 Mar 20	25	-69	59	25
31 Dec 19	27	-70	62	25
30 Sep 19	29	-61	63	22
30 Jun 19	28	-51	55	16
31 Mar 19	27	-43	47	17
31 Dec 18	26	-38	41	19
30 Sep 18	24	-38	37	22
30 Jun 18	25	-36	34	25
31 Mar 18	24	-35	33	24
31 Dec 17	25	-32	33	22
30 Sep 17	25	-29	57	25
30 Jun 17	23	-27	49	18
31 Mar 17	21	-26	40	14
31 Dec 16	21	-23	31	10
30 Sep 16	20	-21	18	10
30 Jun 16	20	-16	18	10
31 Mar 16	21	-12	18	10
31 Dec 15	20	-11	18	10
30 Sep 15	20	-11	20	9
30 Jun 15	19	-12	20	9
31 Mar 15	18	-13	20	9
31 Dec 14	19	-13	20	9
30 Sep 14	18	-15	19	10
30 Jun 14	19	-19	19	10
31 Mar 14	18	-20	19	10
31 Dec 13	17	-22	19	10

Qualität der Erträge: BIOPOR ist derzeit unrentabel.

Wachsende Gewinnspanne: BIOPOR ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: BIOPOR ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 0.03% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von BIOPOR verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: BIOPOR ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Biotechs (-18.2%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: BIOPOR hat eine negative Eigenkapitalrendite (-70.83%), da es derzeit unrentabel ist.

BioPorto Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2024 earnings released: kr.0.04 loss per share (vs kr.0.048 loss in 1Q 2023)

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

BioPorto A/S to Report Nine Months, 2024 Results on Oct 30, 2024

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Recent updates

New minor risk - Market cap size

Bioporto A/S Maintains Revenue Guidance for the Year 2024

BioPorto A/S Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL) for Adult Use at Massachusetts General Hospital

We're Hopeful That BioPorto (CPH:BIOPOR) Will Use Its Cash Wisely

Consensus EPS estimates fall by 80%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bioporto A/S Affirms Earnings Guidance for 2024

New major risk - Share price stability

New minor risk - Shareholder dilution

BioPorto A/S Appoints Niels Høy Nielsen as Member of the Executive Management Team, Effective August 1, 2024

Bioporto A/S Provides Revenue Guidance for 2024

First quarter 2024 earnings released: kr.0.04 loss per share (vs kr.0.048 loss in 1Q 2023)

Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024

Bioporto A/S Announces Tonni Bülow-Nielsennot to Stand for Election

New major risk - Revenue and earnings growth

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

BioPorto A/S Announces CEO Changes

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

BioPorto A/S to Report Nine Months, 2024 Results on Oct 30, 2024

BioPorto A/S, Annual General Meeting, Apr 30, 2024

New major risk - Share price stability

BioPorto A/S Receives FDA 510(k) Clearance for NGAL Test in the United States

BioPorto A/S Announces Resignation of Jan Leth Christensen as Board Member

Consensus estimates of losses per share improve by 16%

New major risk - Financial position

Bioporto A/S Provides Revenue Guidance for the Fiscal Year 2023

Bioporto A/S Announces Resignation of Neil Goldman as CFO

BioPorto A/S announced that it has received $0.11 million in funding

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

BioPorto A/S Maintains Earnings Guidance for the Year 2023

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

New minor risk - Shareholder dilution

High number of new and inexperienced directors

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

BioPorto A/S Maintains Financial Guidance for 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

We're Hopeful That BioPorto (CPH:BIOPOR) Will Use Its Cash Wisely

BioPorto A/S, Annual General Meeting, Apr 27, 2023

BioPorto A/S Appoints Nis Kruse as EVP of Strategic Partnerships and Gm of EMEA & Apac

Less than half of directors are independent

BioPorto A/S Submits Application for Marketing Authorization of NGAL Test to the US Food and Drug Administration

BioPorto A/S Revises Earnings Guidance for the Year 2022

Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth

BioPorto A/S Revises Earnings Guidance for the Year 2022

Second quarter 2022 earnings: Revenues exceed analyst expectations

BioPorto A/S Revises Earnings Guidance for the Year 2022

BioPorto A/S Achieves Targeted Enrollment in Clinical Study Supporting FDA De Novo Submission for The NGAL Test in the U.S

BioPorto A/S Appoints Dr. Prasad Devarajan as New Senior Medical Director

We're Keeping An Eye On BioPorto's (CPH:BIOPOR) Cash Burn Rate

BioPorto A/S Maintains its Earnings Guidance for the Year 2022

Price target decreased to kr.3.50

Less than half of directors are independent

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

BioPorto A/S Provides Earnings Guidance for the Full Year 2022

Is BioPorto (CPH:BIOPOR) In A Good Position To Deliver On Growth Plans?

Consensus forecasts updated

Third quarter 2021 earnings released: kr.0.04 loss per share (vs kr.0.087 loss in 3Q 2020)

Here's Why We're Not Too Worried About BioPorto's (CPH:BIOPOR) Cash Burn Situation

Second quarter 2021 earnings released: kr.0.051 loss per share (vs kr.0.077 loss in 2Q 2020)

BioPorto A/S Maintains Earnings Guidance for the Year 2021

BioPorto A/S Provides Pipeline Update Regarding COVID-19 Test

Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth

First quarter 2021 earnings released: kr.0.06 loss per share (vs kr.0.088 loss in 1Q 2020)

BioPorto A/S Provides Earning Guidance for the Year 2021

Independent Vice Chairman Torben Nielsen has left the company

Independent Director has left the company

Price target decreased to kr.6.00

Consensus revenue estimates fall to kr.30.0m

Full year 2020 earnings released: kr.0.30 loss per share (vs kr.0.41 loss in FY 2019)